122.06
Novartis Ag Adr Aktie (NVS) Neueste Nachrichten
Pharmaceutical Market to Reach USD 3,033.21 Billion by 2034 Driven by Rising Geriatric Population - GlobeNewswire Inc.
Novartis' Strong Branded Drug Portfolio Supports Steady Long-Term Growth - Morningstar
Novartis completes acquisition of Tourmaline Bio - Novartis
Novartis ADR earnings missed by $0.02, revenue topped estimates - Investing.com Nigeria
Novartis to acquire Avidity Biosciences in $12B deal - Proactive financial news
Why Avidity Biosciences Shares Are Trading Higher By Around 42%; Here Are 20 Stocks Moving Premarket - Benzinga
Novartis Cosentyx Trial Shows Efficacy In Patients With Stiff Joints And Muscle Pain - Sahm
Novartis announces expiration of Hart-Scott-Rodino waiting period of Tourmaline Bio tender offer - Novartis
Will Positive Regulatory Updates Further Boost INCY Stock? - The Globe and Mail
Novartis Cancer Drug Shows Sustained Benefit In Five-Year Breast Cancer Trial - Sahm
Small-Cap Biotech Climb Bio's Lead Drug Candidate Has Larger Long-Term Opportunity - Sahm
Novartis Strengthens Kidney Disease Pipeline With Promising Data - Sahm
Next-Generation Targeted Therapies Reshape Precision Oncology Landscape - Sahm
Vor Bio's Collaborator Delivers Positive Results For Telitacicept In Autoimmune Disorder That Impacts Tears - Sahm
Will the Orbital Acquisition Strengthen BMY's Cell Therapy Portfolio? - The Globe and Mail
UBS Reaffirms Their Hold Rating on Novartis AG (NOVN) - The Globe and Mail
Should You Buy Novartis Stock Before October 28? - Barchart.com
Barclays Reaffirms Their Sell Rating on Novartis AG (NOVN) - The Globe and Mail
2 Surefire Dividend Stocks to Buy for the Long Haul - sharewise.com
Novartis: Superstars Entresto And Kisqali Fuel Market Outperformance (NYSE:NVS) - Seeking Alpha
Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU) - Ariva
Pharma's Direct-To-Patient Wave Hits Novartis Next - Sahm
Novartis announces commencement of tender offer to acquire Tourmaline Bio - Novartis
Trump's New Tariff Barrage Targets Drugs, Trucks, Cabinets: President Says Move Will Protect Manufacturers From 'Unfair Outside Competition' - Sahm
Eli Lilly Stock Is Trading Down Thursday: What's Behind The Move? - Sahm
Novartis, AbbVie Face Legal Defeat Over 340B Contract Pharmacies - Sahm
INCY Obtains FDA Approval for Label Expansion of Ruxolitinib Cream - The Globe and Mail
Monte Rosa, Novartis Use AI-Powered Engine To Advance Immune Disease Treatments - Sahm
Novartis (NVS) was downgraded to a Sell Rating at Goldman Sachs - The Globe and Mail
Goldman Sachs Downgrades Novartis (NVS) to Sell Over Risk Concer - GuruFocus
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):